In contrast, smoothened (Smo) antagonists, such as GDC-0049 and Glasdegib, were largely ineffective, suggesting that Gli1 activation in T-ALL primarily occurs through non-canonical, Smo-independent mechanisms. Here, SMO is linked to acute lymphoblastic leukemia.